eligibility_summary
Eligible: adults with relapsed/refractory large B‑cell lymphoma previously treated with Axi‑cel who are non‑CR or relapsed, informed consent, ADA testing before retreatment, CD19 status at investigator discretion, prior fludarabine/cyclophosphamide LDC toxicities ≤ grade 1 or baseline, no serious AEs during initial Axi‑cel or resolved. Exclude: hypersensitivity (incl. DMSO, compound electrolyte injection, human albumin), uncontrolled infections.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Axicabtagene ciloleucel (axi-cel), an autologous, gene-modified anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, given as retreatment in relapsed/refractory large B-cell lymphoma after prior axi-cel non-CR/relapse. Mechanism of action: Patient T cells are engineered to express a CD19-specific CAR with CD28 costimulatory and CD3ζ signaling domains. Upon binding CD19 on B cells, CAR T cells activate, proliferate, release cytotoxic granules and cytokines, and kill malignant B cells. Lymphodepleting chemotherapy (fludarabine/cyclophosphamide) may be used to support CAR-T expansion. Targets: CD19+ malignant B cells (LBCL) and normal B cells, pathways include CAR-driven T-cell activation (CD28/CD3ζ) and downstream cytotoxic effector mechanisms.